Matricelf teams up with TAU on organ 3D printing
Israel Society for Regenerative Medicine and Tissue Engineering Matricelf Ltd. (TASE: MTLF) and Tel Aviv University’s technology transfer company, Ramot, today announced the signing of an exclusive worldwide licensing agreement for the commercialization of an innovative patent technology in the field of 3D bioprinting of tissues and organs. The technology was developed by Professor Tal Dvir from the Department of Biotechnology at the Faculty of Life Sciences and Director of the Center for Nanotechnology at Tel Aviv University, who was one of the founders of Matricelf and is the Director society scientist.
Matricelf develops autologous (bone marrow) implants for the regeneration of damaged tissues and organs in the body, using stem cells and extracellular matrix (ECM) from patients themselves.
Under the terms of the agreement, Matricelf will receive worldwide rights as well as exclusivity to develop and produce the technology used to print organs and tissues, among other indications the company is focused on, and to market the technology for others. This is subject to compliance with scientific and commercial steps. As part of the agreement, the company will undertake to sign, within 36 months from the date of signature of the agreement, at least one marketing agreement with a third party, subject to the approval from Ramot, whether it is a license agreement for this or that specific development, or an investment agreement to develop the technology, etc.
The patent, which is pending for approval in the United States and Europe, covers different aspects of this unique technology, which allows simultaneous 3D printing of cells and extracellular matrix (ECM), for mass production. scale of living human tissues and organs, and which practically includes most organs of the body. The uniqueness of the technology is based on liquid nano-molecules, which stabilize the printed biological structure, even if they are liquid, and allow printing at high resolution and at the highest degree of precision. After printing, the molecules are entirely extracted from the printed structure, and leave it stabilized. Using this technology, a complete heart composed of human cells and extracellular matrix was printed for the first time in the world at Tel Aviv University in 2019.
Matricelf CEO Dr. Asaf Toker said, “We are pleased to accept another collaboration with Tel Aviv University and view this as a strong vote of confidence in the company and its scientific and commercial capabilities. , in the field of tissue engineering, which is the future. 3D bioprinting is at the forefront of this industry, which is growing on average by tens of percentages per year and is expected to be worth billions of dollars by 2024. The application of the technology, both in the development of the company, primarily through the treatment of spinal cord injuries, as well as marketing to various industry partners, significantly increases the company’s value growth potential in the foreseeable future and strengthens its status as a player world leader in the sector. »
Professor Tal Dvir said: “The growing shortage of organs for transplants is driving the need for breakthrough solutions, primarily 3D biological printing of tissues and organs. This field is expected to grow at an accelerated rate over the next decade and we believe that this organ printing technology, which simultaneously combines cells and extracellular matrix, positions us well to realize the company’s vision of becoming a pioneer in the field of regenerative medicine, thanks to the unique tissue and organ printing platform that will provide a cure and save the lives of patients around the world.”
Ramot’s CEO, Keren Primor Cohen, added, “Ramot – Tel Aviv University’s technology transfer company, believes in the ability of Professor Tal Dvir’s breakthrough technology to be a game changer in the tissue engineering sector and to benefit society as a whole. Ramot will continue to invest in and promote such innovative technologies by researchers at the university, in collaboration with leading industry partners such as companies like Matricef.
Published by Globes, Israel business news – en.globes.co.il – on January 30, 2022.
© Copyright Globes Publisher Itonut (1983) Ltd., 2022.